|
SUTRO BIOPHARMA, Inc. (Stro) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Sutro Biopharma, Inc. (STRO) Bundle
Diseñada para la precisión, nuestra calculadora DCF (Stro) le permite evaluar la valoración de Sutro BioPharma, Inc. utilizando datos financieros del mundo real, al tiempo que ofrece una flexibilidad completa para modificar todos los parámetros esenciales para las proyecciones mejoradas.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.7 | 42.7 | 61.9 | 67.8 | 153.7 | 213.0 | 295.2 | 409.2 | 567.0 | 785.8 |
| Revenue Growth, % | 0 | -0.03275927 | 44.84 | 9.52 | 126.84 | 38.58 | 38.58 | 38.58 | 38.58 | 38.58 |
| EBITDA | -46.6 | -23.8 | -98.5 | -105.1 | -67.9 | -170.3 | -236.1 | -327.1 | -453.4 | -628.3 |
| EBITDA, % | -109.08 | -55.6 | -159.22 | -155.03 | -44.18 | -79.96 | -79.96 | -79.96 | -79.96 | -79.96 |
| Depreciation | 4.8 | 4.3 | 9.8 | 8.3 | 6.8 | 22.9 | 31.7 | 43.9 | 60.9 | 84.4 |
| Depreciation, % | 11.18 | 10.06 | 15.79 | 12.23 | 4.43 | 10.74 | 10.74 | 10.74 | 10.74 | 10.74 |
| EBIT | -51.4 | -28.1 | -108.3 | -113.4 | -74.7 | -176.5 | -244.6 | -339.0 | -469.8 | -651.1 |
| EBIT, % | -120.26 | -65.66 | -175.01 | -167.26 | -48.61 | -82.85 | -82.85 | -82.85 | -82.85 | -82.85 |
| Total Cash | 117.9 | 368.1 | 197.9 | 302.3 | 375.6 | 213.0 | 295.2 | 409.2 | 567.0 | 785.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 6.3 | 5.6 | 12.5 | 7.1 | 36.1 | 34.9 | 48.3 | 67.0 | 92.8 | 128.6 |
| Account Receivables, % | 14.74 | 13.01 | 20.13 | 10.51 | 23.47 | 16.37 | 16.37 | 16.37 | 16.37 | 16.37 |
| Inventories | .0 | .0 | .0 | -11.7 | .0 | -7.3 | -10.2 | -14.1 | -19.5 | -27.1 |
| Inventories, % | 0 | 0 | 0.000001616031 | -17.22 | 0 | -3.44 | -3.44 | -3.44 | -3.44 | -3.44 |
| Accounts Payable | 5.6 | 5.5 | 6.0 | 4.8 | 9.4 | 20.9 | 28.9 | 40.1 | 55.5 | 77.0 |
| Accounts Payable, % | 13.07 | 12.98 | 9.71 | 7.08 | 6.14 | 9.79 | 9.79 | 9.79 | 9.79 | 9.79 |
| Capital Expenditure | -3.5 | -7.1 | -15.3 | -7.9 | -4.3 | -27.3 | -37.8 | -52.4 | -72.6 | -100.6 |
| Capital Expenditure, % | -8.15 | -16.69 | -24.76 | -11.59 | -2.81 | -12.8 | -12.8 | -12.8 | -12.8 | -12.8 |
| Tax Rate, % | -20.53 | -20.53 | -20.53 | -20.53 | -20.53 | -20.53 | -20.53 | -20.53 | -20.53 | -20.53 |
| EBITAT | -51.4 | -31.6 | -111.5 | -115.8 | -90.1 | -176.5 | -244.6 | -339.0 | -469.8 | -651.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -50.8 | -33.7 | -123.5 | -99.6 | -123.6 | -160.9 | -253.3 | -351.0 | -486.4 | -674.1 |
| WACC, % | 25.37 | 25.37 | 25.37 | 25.37 | 25.37 | 25.37 | 25.37 | 25.37 | 25.37 | 25.37 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -882.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -688 | |||||||||
| Terminal Value | -2,942 | |||||||||
| Present Terminal Value | -950 | |||||||||
| Enterprise Value | -1,832 | |||||||||
| Net Debt | -36 | |||||||||
| Equity Value | -1,797 | |||||||||
| Diluted Shares Outstanding, MM | 60 | |||||||||
| Equity Value Per Share | -29.86 |
What You Will Get
- Pre-Filled Financial Model: Sutro Biopharma’s actual data enables precise DCF valuation.
- Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers.
- Instant Calculations: Automatic updates ensure you see results as you make changes.
- Investor-Ready Template: A refined Excel file designed for professional-grade valuation.
- Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts.
Key Features
- Comprehensive Data: Sutro Biopharma’s historical financial statements and detailed forecasts.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: View Sutro Biopharma’s intrinsic value recalculated instantly.
- Visual Data Representation: Interactive dashboard charts illustrate valuation results and essential metrics.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- Download: Obtain the ready-to-use Excel file featuring Sutro Biopharma, Inc.'s (STRO) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and compare results instantly.
- Make Decisions: Leverage the valuation outcomes to inform your investment strategy.
Why Choose This Calculator for Sutro Biopharma, Inc. (STRO)?
- Designed for Industry Experts: A sophisticated tool utilized by researchers, financial analysts, and biopharma executives.
- Comprehensive Data: Historical and projected financials for Sutro Biopharma preloaded for precision.
- Flexible Scenario Analysis: Easily simulate various forecasts and assumptions for informed decision-making.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and other critical metrics.
- User-Friendly: Step-by-step guidance ensures a smooth and straightforward experience.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for portfolio assessment related to Sutro Biopharma, Inc. (STRO).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the company.
- Consultants and Advisors: Deliver precise valuation analyses and insights for clients interested in Sutro Biopharma, Inc. (STRO).
- Students and Educators: Leverage real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotechnology firms like Sutro Biopharma, Inc. (STRO) are valued in the investment landscape.
What the Template Contains
- Pre-Filled Data: Includes Sutro Biopharma, Inc.'s (STRO) historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Sutro Biopharma, Inc.'s (STRO) profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.